MedPath

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis

Phase 2
Completed
Conditions
Colitis, Ulcerative
Interventions
Drug: Placebo
Registration Number
NCT00676832
Lead Sponsor
Prometheus Laboratories
Brief Summary

The purpose of this study is to determine whether COLAL-PRED is a safe and effective treatment for patients with moderate to severe ulcerative colitis.

Detailed Description

This is a multi-center, randomized, double-blind, placebo-controlled, parallel-design, dose-ranging study. Eligible patients with a DAI score of 6 to 10 (inclusive), plus endoscopic evidence of moderate to severe ulcerative colitis as assessed by flexible sigmoidoscopy, unless colonoscopy is clinically indicated, and rectal bleeding will be randomized to placebo or one of four doses of COLAL-PRED (equivalent to 40, 60, 80, or 120 mg of prednisolone). The effectiveness and safety of COLAL-PRED will be evaluated at baseline, and after 2 weeks and 4 weeks of treatment. Additional follow-up measurements will take place 7 days post cessation of treatment.

The systemic absorption of COLAL-PRED will be determined by measuring blood levels of prednisolone, prednisolone sodium metasulfobenzoate (PMSBS) and metasulfobenzoate at Week 4.

Hypothalamic-pituitary-adrenocortical (HPA) axis response will be monitored by measuring morning serum cortisol levels at Baseline, Week 2, Week 4, and at follow-up visit and cortisol levels following adrenocorticotrophic hormone (ACTH) stimulation testing at Baseline and Week 4.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
190
Inclusion Criteria
  • Females must be of non-childbearing potential evidenced by being surgically sterile, postmenopausal for at least 12 months or be using acceptable contraception methods such as contraceptive pill, or two forms of barrier contraception.

  • Disease Activity Index (DAI) Score of 6-10 (inclusive) at the Baseline Visit.

  • Previous colonoscopic and biopsy diagnosis of ulcerative colitis with negative evaluation of the ileum within 3 years of the screening visit.

  • Endoscopic evidence of moderate or severe mucosal disease as assessed by flexible sigmoidoscopy, with a minimum confirmed diagnosis of moderate ulcerative colitis.

  • The following concomitant prescription medications for ulcerative colitis are permitted if the following conditions are met:

    1. Oral 5-aminosalicylic acid (5-ASA )therapy if the following 2 criteria are met:

      1. Must be on a stable dose 2 weeks prior to baseline
      2. Must maintain the stable dose until treatment end.
    2. Azathioprine or 6-mercaptopurine or methotrexate if the 4 following criteria are met:

      1. On therapy continually for at least 3 months prior to baseline.
      2. And on a stable dose for at least 2 weeks prior to baseline.
      3. And must maintain the stable dose until the end of study drug treatment.
Exclusion Criteria
  • History of colonic or rectal surgery, excluding hemorrhoidal surgery or an appendectomy.
  • Pregnant or breast-feeding females.
  • Diagnosis of diabetes, heart failure, unstable angina, hepatic cirrhosis, kidney failure, adrenocortical insufficiency, or any other unstable medical condition.
  • Known hypersensitivity to corticosteroids
  • Use of oral 5-aminosalicylic acid (5-ASA) or oral corticosteroids during the immediate screening period.
  • Use of immunosuppressive drugs or antibiotics at any time within four weeks prior to screening.
  • Diagnosis of Crohn's disease; indeterminate colitis; microscopic colitis; ischemic, infectious (e.g., salmonella, shigella, etc.), or amebic colitis; or gonococcal proctitis; Clostridium difficile colitis.
  • History of tuberculosis or HIV
  • Clinically significant abnormal laboratory test results, unless regarded by the Investigator as related to ulcerative colitis
  • History of alcohol or drug abuse
  • Known malignancy or history of malignancy that would reduce life expectancy
  • Recent immunization with live viral vaccines
  • History of or active peptic ulcer disease or gastritis
  • Generalized infections such as systemic fungal or hepatitis B or C
  • History of steroid induced severe hypertension, steroid-induced psychosis, or any other severe steroid-related adverse reaction

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1Placebo-
Group 2COLAL-PRED-
Group 3COLAL-PRED-
Group 4COLAL-PRED-
Group 5COLAL-PRED-
Primary Outcome Measures
NameTimeMethod
The proportion of patients with Complete Response at Week 4 defined as a decrease from baseline in the DAI score by ≥ 30% or ≥ 3 points, and with a decrease in the rectal bleeding subscore of ≥ 1 or an absolute rectal bleeding sub-score of 0 or 1.Week 4 of the study or at time of withdrawal
Secondary Outcome Measures
NameTimeMethod
The proportion of patients in Clinical Remission defined as a DAI score of ≤ 2 points, with no-individual DAI sub-score > 1 at Week 4. Patients in remission by this definition will have a rectal bleeding DAI sub-score of either 0 or 1.Week 4

Trial Locations

Locations (88)

Prometheus Investigational Site # 001

🇺🇸

Chicago, Illinois, United States

Prometheus Investigational Site #069

🇺🇸

Columbus, Ohio, United States

Prometheus Investigational Site #037

🇺🇸

Boston, Massachusetts, United States

Prometheus Investigational Site #008

🇺🇸

Miami, Florida, United States

Prometheus Investigational Site #046

🇺🇸

Hagerstown, Maryland, United States

Prometheus Investigational Site #022

🇺🇸

San Diego, California, United States

Prometheus Investigational Site #026

🇺🇸

San Antonio, Texas, United States

Prometheus Investigational Site #073

🇺🇸

San Antonio, Texas, United States

Prometheus Investigational Site #053

🇺🇸

Nashville, Tennessee, United States

Prometheus Investigational Site #010

🇺🇸

Arlington Heights, Illinois, United States

Prometheus Investigational Site #005

🇺🇸

Atlanta, Georgia, United States

Prometheus Investigational Site #086

🇺🇸

West Covina, California, United States

Prometheus Investigational Site #044

🇺🇸

Atlanta, Georgia, United States

Prometheus Investigational Site #097

🇺🇸

Lafayette, Colorado, United States

Prometheus Investigational Site #051

🇺🇸

Topeka, Kansas, United States

Prometheus Investigational Site #052

🇺🇸

Santa Monica, California, United States

Prometheus Investigational Site #081

🇺🇸

Huntsville, Alabama, United States

Prometheus Investigational Site #091

🇺🇸

Southbridge, Massachusetts, United States

Prometheus Investigational Site #039

🇺🇸

Baton Rouge, Louisiana, United States

Prometheus Investigational Site #019

🇺🇸

Mexico, Missouri, United States

Prometheus Investigational Site #059

🇺🇸

Anderson, Indiana, United States

Prometheus Investigational Site #065

🇺🇸

Little Rock, Arkansas, United States

Prometheus Investigational Site #060

🇺🇸

Palm Springs, California, United States

Prometheus Investigational Site #049

🇺🇸

Tulsa, Oklahoma, United States

Prometheus Investigational Site 041

🇺🇸

Chicago, Illinois, United States

Prometheus Investigational SIte #036

🇺🇸

Thornton, Colorado, United States

Prometheus Investigational Site #076

🇺🇸

Hollywood, Florida, United States

Prometheus Investigational Site #066

🇺🇸

Winter Park, Florida, United States

Prometheus Investigational Site #089

🇺🇸

Peoria, Illinois, United States

Prometheus Investigational Site #015

🇺🇸

Davenport, Iowa, United States

Prometheus Investigational Site #018

🇺🇸

Braintree, Massachusetts, United States

Prometheus Investigational Site 092

🇺🇸

New Orleans, Louisiana, United States

Prometheus Investigational Site # 050

🇺🇸

Chesterfield, Michigan, United States

Prometheus Investigational Site #021

🇺🇸

Jackson, Mississippi, United States

Prometheus Investigational Site 100

🇺🇸

Shreveport, Louisiana, United States

Prometheus Investigational Site #009

🇺🇸

Egg Harbor Township, New Jersey, United States

Prometheus Investigational Site #070

🇺🇸

Dayton, Ohio, United States

Prometheus Investigational Site 087

🇺🇸

Stony Brook, New York, United States

Prometheus Investigational Site #047

🇺🇸

Greenville, North Carolina, United States

Prometheus Investigational Site #084

🇺🇸

Franklin, Tennessee, United States

Prometheus Investigational Site #082

🇺🇸

Sugar Land, Texas, United States

Prometheus Investigational Site #012

🇺🇸

Ogden, Utah, United States

Prometheus Investigational Site #042

🇺🇸

Huntsville, Alabama, United States

Prometheus Investigational Site #067

🇺🇸

Scottsdale, Arizona, United States

Prometheus Investigational Site #033

🇺🇸

Montgomery, Alabama, United States

Prometheus Investigational Site #068

🇺🇸

Jonesboro, Arkansas, United States

Prometheus Investigational Site 062

🇺🇸

Fresno, California, United States

Prometheus Investigational Site #090

🇺🇸

Tucson, Arizona, United States

Prometheus Investigational Site #093

🇺🇸

Lowell, Arkansas, United States

Prometheus Investigational Site #057

🇺🇸

Madera, California, United States

Prometheus Investigational Site #095

🇺🇸

Roseville, California, United States

Prometheus Investigational Site #006

🇺🇸

Littleton, Colorado, United States

Prometheus Investigational Site #083

🇺🇸

Hartford, Connecticut, United States

Prometheus Investigational Site #023

🇺🇸

Cape Coral, Florida, United States

Prometheus Investigational Site #007

🇺🇸

Jacksonville, Florida, United States

Prometheus Investigational Site #075

🇺🇸

Cape Coral, Florida, United States

Prometheus Investigational Site #027

🇺🇸

Sarasota, Florida, United States

Prometheus Investigational Site #061

🇺🇸

Lafayette, Louisiana, United States

Prometheus Investigational Site #035

🇺🇸

Laurel, Maryland, United States

Prometheus Investigational Site #025

🇺🇸

Lutherville, Maryland, United States

Prometheus Investigational Site #011

🇺🇸

Novi, Michigan, United States

Prometheus Investigational Site #072

🇺🇸

Wyoming, Michigan, United States

Prometheus Investigational Site #098

🇺🇸

Plymouth, Minnesota, United States

Prometheus Investigational Site #017

🇺🇸

Lebanon, New Hampshire, United States

Prometheus Investigational Site #063

🇺🇸

Ocean, New Jersey, United States

Prometheus Investigational Site #080

🇺🇸

Brooklyn, New York, United States

Prometheus Investigational Site #014

🇺🇸

Cedar Knolls, New Jersey, United States

Prometheus Investigational Site #002

🇺🇸

Great Neck, New York, United States

Prometheus Investigational Site #079

🇺🇸

Rochester, New York, United States

Prometheus Investigational Site 043

🇺🇸

Rockville Center, New York, United States

Prometheus Investigational Site #013

🇺🇸

Charlotte, North Carolina, United States

Prometheus Investigational Site #058

🇺🇸

Wilmington, North Carolina, United States

Prometheus Investigational Site #064

🇺🇸

Dayton, Ohio, United States

Prometheus Investigational Site #055

🇺🇸

Mentor, Ohio, United States

Prometheus Investigational Site #038

🇺🇸

Philadelphia, Pennsylvania, United States

Prometheus Investigational Site #094

🇺🇸

Westlake, Ohio, United States

Prometheus Investigational Site #028

🇺🇸

Tulsa, Oklahoma, United States

Prometheus Investigational Site #030

🇺🇸

Philadelphia, Pennsylvania, United States

Prometheus Investigational Site #034

🇺🇸

Sayre, Pennsylvania, United States

Prometheus Investigational Site #020

🇺🇸

Germantown, Tennessee, United States

Prometheus Investigational Site 101

🇺🇸

Denton, Texas, United States

Prometheus Investigational Site #074

🇺🇸

Union City, Tennessee, United States

Prometheus Investigational Site #071

🇺🇸

Plano, Texas, United States

Prometheus Investigational Site #040

🇺🇸

Seattle, Washington, United States

Prometheus Investigational Site #045

🇺🇸

Charleston, South Carolina, United States

Prometheus Investigational Site #003

🇺🇸

San Carlos, California, United States

Prometheus Investigational Site #031

🇺🇸

Hamden, Connecticut, United States

Prometheus Investigational Site #016

🇺🇸

Chevy Chase, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath